Raj Prem – Thrilled to Learn About Bob Bonis’ Previously Unpublished Rolling Stones Photographs

Mar 27, 2017

Prem has taken his collection across the world, sharing the shots he collected over the course of 18 years and often exhibiting them at SFAE, London’s Atlas Gallery, Snap Gallery, and Proud Galleries, which show some very rare Abbey Road prints.

NEW YORK, NY - March 27, 2017 /MarketersMedia/ —

Acclaimed curator and music photography collector Raj Prem was enraptured to discover the 200 special-edition fine art prints of the Rolling Stones, which appeared on eBay as of February. He believes these photos to be a treasure for the lovers of rock history and photography

The 200 images are part of 3,500 previously unpublished photos shot by Bob Bonis, U.S. tour manager of the Beatles and Rolling Stones between 1964 and 1966. The images remained private throughout Bonis’ life and stayed undiscovered in his basement even after his death in 1992. It was only until five years ago that the photos saw the light of day, when Bob’s son, Alex Bonis, decided to roll out 10 pictures per month over the period of two years. Sold through eBay’s art and collectibles store, the photos are priced starting from $175 for 11 by 14 inch prints all the way to over $625 for 20 by 24 inch prints. They are sold first-come-first-serve rather than through an auction and 10% of the proceeds will benefit the Grammy Foundation, the Grammy Museum, and other renowned charities. The Grammy Museum also volunteered to provide a certificate of authenticity with each limited-edition print, a gesture Prem believes can increase the value of the pictures and make them worth more than their actual cost.

Depicting the history of rock music between 1963 and 1972, Raj Prem’s collection has been exhibited in different countries and galleries worldwide, including the U.S., U.K., Dubai, Japan, and the Netherlands. He has critically acclaimed exhibitions to his name such as The Decca Years, which features the works of Philip Townsend, Michael Cooper, and Dominique Tarle during the band’s rise from chart hits to rock movement leaders. Prem is very much interested in Bonis’ Beatles photographs to complement the many pieces he has showcased in more than 95 exhibitions, featuring the works of photographers like Robert Freeman, David Hurn, Iain Macmillan et al, who have immortalized John Lennon, Paul McCartney, George Harrison, and Ringo Starr for over four decades.

Owner of the extensive Raj Prem Fine Art Photography collection depicting iconic bands such as The Rolling Stones and The Beatles, Prem is passionate about music from the 1960s and the 1970s. The former music journalist became an avid collector after a conversation with SFAE gallery owner Theron Kabrich in 1996. Within just one year, he had numerous epochal pictures to take part in SFAE’s first rock photography show, which was also the first of its kind worldwide. Prem has taken his collection across the world, sharing the shots he collected over the course of 18 years and often exhibiting them at SFAE, London’s Atlas Gallery, Snap Gallery, and Proud Galleries, which show some very rare Abbey Road prints. In addition, he has provided rights to publications such as FT.com and NME.com, allowing them to post some of these images on their sites or magazines, contributing to the worldwide distribution of some of the most iconic shots ever taken of the beloved rock stars.

Raj Prem - Fine Art Photography: http://rajpremnews.com

Raj Prem -- To Publish New Book About His Career in Music Photography: http://finance.yahoo.com/news/raj-prem-publish-book-career-034420648.html

Raj Prem - Financial Times: https://www.ft.com/content/2b312c24-6570-11e0-b150-00144feab49a

Contact Info:
Name: RPN
Email: [email protected]
Organization: Raj Prem Fine Art Photography

Source URL: http://marketersmedia.com/raj-prem-thrilled-to-learn-about-bob-bonis-previously-unpublished-rolling-stones-photographs/181057

For more information, please visit http://www.RajPremNews.com

Source: MarketersMedia

Release ID: 181057

More News

US wholesale inflation reaches levels last seen in 2022

Oct 15, 2026

US wholesale inflation reaches levels last seen in 2022

WASHINGTON — Wholesale inflation rose more than expected last month on a big jump in fuel costs as rising prices become a bigger economic challenge for millions of Americans, and a growing political problem for Republicans in the upcoming midterm elections. The Labor Department’s producer price index — which captures inflation before it reaches consumers — soared 6.3 percent in September from a year ago, up from 5.6 percent in August and the biggest increase since December 2022, the government said Thursday. On a monthly basis, wholesale prices rose 1.3 percent from August to September, marking the largest increase since March 2022, after a 0.5 percent gain the previous month. The data indicated that rising fuel prices, particularly for the diesel fuel used by long-haul trucks and freight trains, is pushing up the cost of shipping and warehousing goods. That is starting to lift the cost of food, one place where prices appeared to have cooled this year. Wholesale food prices jumped 1.2 percent just from August to September, though they are still unchanged from a year ago. Transport

Venezuela's Maduro and wife plead not guilty to US torture charges

Oct 15, 2026

Venezuela's Maduro and wife plead not guilty to US torture charges

NEW YORK — Ousted Venezuelan President Nicolas Maduro and his wife Cilia Flores pleaded not guilty on Thursday to a new US indictment accusing them of conspiring to torture political opponents. The additional charges, brought last Thursday, significantly expanded the US criminal case against Maduro, 63, and Flores, 70. They previously pleaded not guilty to charges that they abused their power to help drug traffickers ship cocaine. Maduro and Flores, captured by the US military in a January raid ordered by President Donald Trump and flown to New York, entered their pleas at an arraignment before US District Judge Alvin Hellerstein in Manhattan federal court. Prosecutors with the Manhattan US Attorney's office say Maduro directed officials to torture opposition politicians and military personnel accused of plotting against him to maintain power in the South American country. In one alleged incident described in the indictment, Maduro in 2014 directed officials to kidnap military personnel to draw information out of them about possible dissidents, and told officials to "squeeze them harde

How Aramco learned to keep pumping oil under fire

Oct 15, 2026

How Aramco learned to keep pumping oil under fire

LONDON — When attack drones struck Saudi Aramco's biggest oil pipeline last month, satellite images showed one of its pumping stations burnt to ashes. By the next day, scores of bulldozers were already building a new pipeline. Within days pumping resumed. The speed of the recovery illustrates how the world's biggest oil producer has transformed its ability to operate under attack after years of assaults on energy infrastructure across the region. "Today, our teams can handle multiple incidents simultaneously, and we continue to build this capability," Saudi state oil firm Aramco's chief executive Amin Nasser told Reuters in an interview last week. Nasser said Aramco has built specialised rapid-response teams, expanded emergency stockpiles for repairs and deployed drones to assess damage even while incidents are still unfolding. Lessons on how to operate under fire came after drones and missiles hit Aramco's major oil processing facility in Abqaiq in 2019, temporarily knocking out half of Aramco's production. "After Abqaiq in 2019, we came up with the idea of rapid response teams, or what

Houthis attack presidential palace complex in Yemen's Aden, PM unharmed, officials say

Oct 15, 2026

Houthis attack presidential palace complex in Yemen's Aden, PM unharmed, officials say

Yemen's Houthis fired missiles at the presidential palace complex in the southern city of Aden on Thursday, killing two security guards, two government officials told Reuters. Yemen's prime minister and cabinet members who were at the Maashiq presidential palace complex were unharmed, Information Minister Moammar al-Eryani said, adding that the Houthis had fired five missiles at the complex. The Houthi-run Saba news agency, citing a military official, said the group had targeted a military operations headquarters run by Saudi officers at the complex, as well as weapons depots. Reuters could not independently verify the claims. The Iran-aligned group's military spokesperson, Yahya Saree, said the strike on what he described as a Saudi military operations headquarters in Aden was part of the group's declared policy of "targeting Saudi military build-ups wherever they are." Three witnesses had earlier told Reuters they heard loud booms in the vicinity of the palace.

Trump scraps plan to livestream execution after broad backlash

Oct 15, 2026

Trump scraps plan to livestream execution after broad backlash

WASHINGTON — The firing squad execution of a convicted military base shooter will not be livestreamed, U.S. President Donald Trump announced Thursday, canceling a contentious plan by Defense Secretary Pete Hegseth. The move to livestream Nidal Hasan's execution was widely opposed at home and abroad, prompting outrage from both U.S. Democratic and Republican politicians, the Catholic Church and the United Nations. The cancellation is a blow to Hegseth, who is already under fire over the stalemated Iran war and its fallout, which are weighing on Trump's Republican Party ahead of November midterm elections. Hasan "will die, as scheduled, by firing squad, but this event will not be streamed," Trump said in a post on his Truth Social platform. The U.S. president indicated he did not personally oppose the streaming plan, saying it "might have been a strong deterrent for the World to witness how America deals with Terrorists and SCUM like Hasan." But "many very good and well meaning people would rather not watch him die," Trump said, adding that the execution could still be viewed in person by

Prince Harry and wife Meghan make first joint appearance since UK return

Oct 15, 2026

Prince Harry and wife Meghan make first joint appearance since UK return

NOTTINGHAM, England — Prince Harry and his wife Meghan appeared together in public on Thursday for the first time since they made a surprise return to Britain, revisiting the city where they made their maiden joint official engagement nine years ago. Harry, the younger son of King Charles, and Meghan shocked the monarch and other members of the royal family when they relocated from California to England two months ago with their children Prince Archie, 7, and Princess Lilibet, 5. In their first joint public outing since then, the couple returned to Nottingham in central England which they visited in 2017, shortly after it was announced they were getting married. "It’s great to be back," Harry said. "Wonderful and great to be back in Nottingham, too." They began by visiting a recording studio run by a youth and community charity which has received support from a £1.1 million ($1.46 million) donation announced by Harry last year. At their next stop at the Himmah charity, which tackles food poverty, Meghan was reunited with four contributors to a charity cookbook released to raise funds

US Army sounds alarm: Why America is preparing for attacks on its own soil

Oct 15, 2026

US Army sounds alarm: Why America is preparing for attacks on its own soil

Gen. Christopher LaNeve, the Army's acting chief of staff, said the US military could face significant challenges deploying forces against a major adversary

Live updates: Zacharia downplays bar exam; Trump quashes Hegseth's plan to livestream execution

Oct 15, 2026

Live updates: Zacharia downplays bar exam; Trump quashes Hegseth's plan to livestream execution

President Trump said Thursday the plan to livestream the execution of Nidal Hasan, the former U.S. Army major who killed 13 people in the 2009 attack on Fort Hood, would not go forward. Trump cited the substantial criticism that had accompanied Defense Secretary Pete Hegseth's plan, saying that while Hasan deserved to be executed, it...

'It is clear that sooner or later we will have European casualties', Romanian MEP

Oct 15, 2026

'It is clear that sooner or later we will have European casualties', Romanian MEP

Rescuers searched on Thursday for seven missing sailors after drones struck two chemical tankers near Romania's Black Sea coast, setting them ablaze and raising fresh security concerns along a vital shipping route used by Ukraine. Speaking with FRANCE 24's Europe editor Armen Georgian, Nicolae Stefanuta, Romanian MEP and Co-Chair of the Group of the Greens, says that the Danube delta region is facing a more intense threat from Russia than Baltic States and that "it is clear that sooner or later we will have European casualties".

NOAA issues new US winter forecast - and a snow warning for East Coast cities

Oct 15, 2026

NOAA issues new US winter forecast - and a snow warning for East Coast cities

The weather agency is forecasting that parts of all of 39 states will see a wetter-than-usual winter

Why your health insurance is dropping GLP-1 coverage

Oct 15, 2026

Why your health insurance is dropping GLP-1 coverage

The promise of GLP-1 drugs has always depended on people being able to afford them. These drugs still cost hundreds of dollars per month if you’re paying cash, at which point access becomes a privilege: The higher-income executive who wants to trim a few pounds might be able to afford them either way, but the low-income worker who needs the drug to lose significant weight might not be able to afford them — unless their health insurance covers it. For a while, the trend lines for GLP-1 insurance coverage were positive. As of 2026, roughly two-thirds of private employer plans, which insure half of Americans, were covering GLP-1 medications for weight loss to treat obesity. Over the summer, Medicare launched a new $50-per-month prescription program. The US has struggled with an obesity epidemic for decades, but it looked like powerful drugs to treat it were finally starting to be more seamlessly integrated into the health system. At least that’s how things appeared earlier this year. But now, private plans are pulling back from GLP-1 coverage. People are being left in the lurch, debating whether to try to pay for these drugs on their own or stop taking medicines they feel are making a real difference for their health. The dilemma reveals one of the structural flaws in American healthcare. For working-age adults, your insurance depends on your job. Unfortunately, because people no longer stay at the same job for decades, there is not a strong financial incentive for employers to make investments that will benefit your health in the long term — but there is a strong incentive to minimize short-term costs as much as possible. It’s the kind of perverse rationale that could compel employer-sponsored health plans to stop covering a drug that, if taken over the full course of a person’s life, could help them not only lose weight but ultimately reduce their risk of heart disease, kidney disease and other chronic health problems, improving their health and saving all of us money as they get older. “An employer or an insurer making coverage decisions doesn’t necessarily care if they’re saving Medicare money,” said Dan Sacks, a healthcare economist at the University of Wisconsin-Madison. “That’s a classic problem with the American health insurance system, and it’s certainly salient here.” This mismatch between what’s good for people’s health and what’s good for the corporate bottom line has long been one of the underlying flaws in the US health system. Now access to GLP-1 drugs is shrinking just as these drugs were starting to make a real dent in the US obesity crisis. The stakes couldn’t be higher. Why employer-sponsored health plans are suddenly dropping GLP-1 coverage From the beginning, insurance coverage was the big question hanging over GLP-1s and their potential to revolutionize US healthcare. But recently, it looked like we’d turned a corner. When I attended the Aspen Ideas: Health festival this summer, pharmaceutical reps seemed visibly relieved that GLP-1 coverage had been picking up among private insurers. In 2026, about two out of every three employer-sponsored plans were covering some of these drugs for weight management, up from about 20 percent just the year before. “They’re recognizing that this is an investment in their workforce,” said Laura Steele, who leads the cardiometabolic health unit at Eli Lilly, which manufactures Zepbound and Foundayo. “Yes, there is a budget, and there is a benefit design that every employer has. That’s real. That’s not going away. But they’re also recognizing the overall cost that they’re experiencing by not dealing with this too.” But as employers and private insurers make coverage decisions for next year, they are suddenly pulling back. At least 10 percent of employer plans that currently cover GLP-1s for weight loss say they are likely to discontinue coverage in 2027, according to one survey by the Business Group on Health — and that number may still increase. A Mercer survey of large employers found that 6 percent had dropped coverage in 2026 and another 5 percent were planning to in 2027 or actively considering it. A separate report from the Health Policy Commission in Massachusetts found that the number of commercially insured people in the state taking a GLP-1 drug had fallen by 50 percent between 2025 and the first quarter of 2026 as private coverage started to drop off.  Some of the biggest brands in the US are reportedly eliminating or reducing their coverage: PepsiCo, Starbucks, and Lowe’s among them. And their reasons are simple: It’s too expensive. The drugs still carry a high net price tag — $600 or more for a 30-day supply — and potential demand is high (2 in every 5 American adults have obesity).  When a lot of people start taking an expensive medication all at once, it’s going to raise costs for employer insurance plans — and they have to figure out how to adapt. Insurers set premiums at the start of each year, based on how many people are on the plan and how much healthcare they are expected to need. But if those estimates are off — say, if more people take an expensive GLP-1 drug than the insurer expected — they have to offset those costs somehow, and raising premiums the following year is a common solution. According to one estimate, premiums are projected to grow by 5 to 13 percent due to GLP-1 costs — and the burden of paying those higher premiums is likely to fall on the workers. The employer can also try to limit GLP-1 use by, for example, asking workers to pay more out of pocket for these drugs; according to Mercer, 27 percent of large US employers instituted some kind of utilization controls for GLP-1 drugs over the past year or plan to next year. They also have the option to simply stop covering these drugs for weight loss altogether — and that’s the route more and more of them are deciding to take. The abrupt reversal has even caught economists like Sacks off guard. 3 big reasons employer health plans are dropping GLP-1 coverage Employers aren’t invested in people’s long-term health: As Americans switch jobs more often, companies want to cut short-term costs. GLP-1 prices are still high, upwards of $600 per month per person for insurers. A lot of people are eligible to take them for weight loss; 2 in 5 US adults have obesity. “I was surprised that anyone would do an about-face because I thought they understood the trade-offs well,” Sacks said. “My guess is that it turned out to be more expensive than they anticipated: take-up is higher, and possibly more people are sticking with it. That’s one reason that you might not want to continue to offer it.” For employers, the short-term costs of covering a drug often outweigh the long-term benefits that medication may confer, at least from the employer’s POV. One analysis — notably produced by Blue Cross Blue Shield Kansas — concluded that covering GLP-1s for weight loss increased average employee health costs by $7,000 in the first year and another $4,200 in the second, largely due to the cost of the drugs themselves. And yet at the same time, there were no decreases in obesity-related medical events in that time period. Another study from Sacks and his colleagues at Indiana University and the University of South Carolina found that GLP-1 use did not lead to any cost savings over five years. So in the short term, these employers are arguably making an economically rational decision — but one that may still come at their employees’ expense. “I’m completely screwed,” said one person on Reddit about Cigna’s plans to drop GLP-1 coverage for their own employees. They’re looking at at least $300 for one month’s supply at cash prices.  They weren’t alone either: “I’m devastated,” said another person, commenting on Starbucks’s decision to stop covering GLP-1 drugs. They said they had an autoimmune condition that had made it difficult to lose weight — until this new class of medicines came along. Where GLP-1 coverage goes from here How could we end up here, where it makes good business sense for companies to make a decision that could potentially harm their workers’ health in the long term? It is at least in part a result of the haphazard way the US has ended up insuring people. When employer-sponsored insurance started to arise in the mid-20th century, eventually becoming the primary way to cover the working-age population, people tended to stay at the same job for a long period of time. In theory, there was a synergy: Companies wanted their workers to stay productive, and so it was worth it for the company to invest in their long-term health via their insurance benefits. And research has found that people who stay with the same company — and the same insurance plan — tend to have better health than those who switch a lot. But these days, people change jobs all the time or work various gigs to piece together an income. You probably don’t expect to stay at your job for 10 years — and your employer doesn’t expect you to either. Instead, they want to keep their own costs as low as possible in the short term. This leads them to cut GLP-1 coverage, even though doctors do believe that people could benefit tremendously long term from the weight loss these drugs help them achieve and all of its potential health benefits.  “There are very real health benefits of these drugs,” Sacks told me. “The fact that we don’t find offsets or they’re even more expensive than we thought doesn’t necessarily mean that we shouldn’t cover them.” Sign up for the Good Medicine newsletter Our political wellness landscape has shifted: new leaders, shady science, contradictory advice, broken trust, and overwhelming systems. How is anyone supposed to make sense of it all? Vox’s senior correspondent Dylan Scott has been on the health beat for a long time, and every week, he’ll wade into sticky debates, answer fair questions, and contextualize what’s happening in American healthcare policy. Sign up here. In theory, the market is supposed to fix the

EXPLAINER: What is the 'hospital of the popes' where Leo is recovering from surgery?

Oct 15, 2026

EXPLAINER: What is the 'hospital of the popes' where Leo is recovering from surgery?

Rome's Gemelli Hospital, where Pope Leo is recovering after surgery for lung cancer, is known as the "hospital of the popes".

Recommended

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Central News Today

Central News Today breaks down complex issues with unique perspective, bringing high-quality journalism to millions of readers around the world.

ABOUT US
NEWSLETTER

Copyright © 2015 - 2026 Central News Today. All Rights Reserved.